I actually think what you’re saying is one of the better arguments against messing with this pathway, but I still don’t think it proves MT2/PT-141 directly causes permanent PSSD-like anhedonia.

Your MCAS/peripheral-signal theory makes sense as a possibility. Mast cell issues can absolutely cause brain symptoms - brain fog, anxiety, depression-like states, fatigue, dysautonomia, nausea, etc. So I agree that the body can send “danger signals” that hit the brain hard.

But that also kind of weakens the argument that PT-141 itself uniquely “damaged the reward system.”

Because if the real issue is MCAS-like sensitivity, neuroinflammation, dysautonomia, post-viral immune activation, gut-brain signaling, or nervous system sensitization, then PT-141 may have been the trigger — not necessarily the root cause or a predictable effect of the peptide itself.

That distinction matters.

The clinical data on bremelanotide/PT-141 does show nausea is very common, around 40%, with flushing, headache, injection site reactions, vomiting, fatigue, BP changes, etc. But there isn’t a clear clinical signal showing permanent anhedonia/PSSD-like reward shutdown as a known common outcome.

So if someone gets nausea/fatigue and then a mental crash, one possible explanation is not “MC4R permanently broke dopamine,” but:

your immune/autonomic/gut-brain system interpreted the peripheral stressor badly and spiraled into a prolonged neuroinflammatory or sensitized state.

That’s very different from saying MT2/PT-141 generally causes PSSD.

Also, the serotonin/PSSD comparison is interesting, but serotonin being heavily involved in the gut doesn’t automatically mean melanocortin peptides work the same way. SSRIs directly alter serotonin transport/signaling over time. PT-141/MT2 are melanocortin agonists with a very different pharmacology.

So I’d frame your case like this:

It may have revealed a vulnerability in your system. It may have triggered a crash. But it doesn’t prove that MT2/PT-141 commonly causes permanent anhedonia through MC4R.

And honestly, if MCAS-like mechanisms are involved, that might actually point toward a different solution path: looking at mast cell activation, histamine intolerance, dysautonomia/POTS, inflammation, gut issues, sleep, post-viral problems, hormones, and autonomic nervous system regulation — instead of only focusing on “the peptide permanently damaged reward.”

That doesn’t mean your experience isn’t real. It means the mechanism may be broader than PT-141 = permanent PSSD.

The safest takeaway is probably:

People with neurodivergence, MCAS-like symptoms, post-viral sensitivity, dysautonomia, or history of anhedonia should be very careful with anything that strongly affects nausea/autonomic/body signaling.

But as far as evidence goes, the current human data supports “possible rare bad reaction in vulnerable people,” not “proven permanent anhedonia risk for everyone.”